What is this summary about? This is a plain language summary of a clinical study of a medicine called lowsodium oxybate (or LXB, also known as Xywav®) in adults with idiopathic hypersomnia.Idiopathic hypersomnia is a rare sleep disorder that makes people have extreme sleepiness during the day. It also can make them sleep a long time at night and during the day, and make it hard for them to fully wake up.This study looked at changes in idiopathic hypersomnia symptoms after participants took LXB for 12 to 16 weeks, and then either switched to placebo for 2 weeks or kept taking LXB for 2 more weeks. The placebo did not contain any medicine, but it looked and tasted like LXB. By comparing results from the placebo and LXB groups, researchers could see if LXB helped symptoms of idiopathic hypersomnia, as well as the impacts of those symptoms on day-to-day functioning and quality of life.
No takes yet. Share an insight, caveat, or question.
Dauvilliers et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: